Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. reports recurring financial and operating updates as a life-sciences reagent manufacturer serving therapy, vaccine and molecular-diagnostics workflows. The company organizes revenue around Lab Essentials and Clinical Solutions, with products that include agar plates, microbial culture and cryopreservation media, buffers, molecular biology reagents and water used across research-use and GMP production settings.
Company news commonly covers quarterly and annual results, revenue guidance, segment performance, Clinical Solutions customer activity, cash use, borrowings and free cash flow. Updates also describe Teknova’s modular manufacturing platform and its role in supplying foundational reagents for genomics, synthetic biology, molecular diagnostics and emerging therapeutic modalities.
Teknova (Nasdaq: TKNO) has appointed Ken Gelhaus as Chief Commercial Officer and Jennifer Henry as Senior Vice President of Marketing. Gelhaus, with over 15 years of experience in life sciences, aims to build a successful sales team to drive growth. Henry, a veteran in branding, will bring a consumer-oriented approach to the company’s marketing strategy. This leadership change is expected to enhance Teknova’s capabilities in commercial operations and brand strategy, potentially accelerating growth in the life sciences sector.
Alpha Teknova, Inc. (TKNO) plans to disclose its third-quarter 2021 financial results on November 10, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET, allowing investors to access the discussion live via their website. Teknova specializes in providing essential reagents for biopharmaceutical development, focusing on agility and customization. The company’s proprietary processes cater to various applications like gene therapy and molecular diagnostics, aiming to accelerate breakthroughs in life sciences.
Teknova reported $8.3 million in total revenue for Q2 2021, marking a 38% year-over-year increase from $6 million. Revenue excluding Sample Transport medium rose 41% from the previous year. However, gross profit decreased to $3.4 million with a 40.4% margin, down from 57.4% in Q2 2020. Operating expenses surged to $5.9 million, driven by increased headcount. The net loss was $2.3 million, compared to net income last year. Teknova retains a strong cash position of $108 million, supporting long-term growth investments.
Alpha Teknova, Inc. (Nasdaq: TKNO) announced it will report its Q2 2021 financial results on August 11, 2021, after market close. A conference call will occur at 4:30 p.m. ET to discuss these results and provide a business update. Teknova specializes in critical reagents for biopharmaceutical development, including drug therapies and vaccines. The company's focus is on agility and customization, delivering GMP products across various applications like cell and gene therapy and mRNA therapeutics.
Alpha Teknova, Inc. (Nasdaq: TKNO) announced the closing of its initial public offering (IPO) on June 29, 2021, selling 6,900,000 shares at $16.00 each. The offering included 900,000 shares from underwriters' options, generating approximately $110.4 million in gross proceeds. The shares began trading on Nasdaq on June 25, 2021. Cowen and William Blair acted as joint book-running managers for the offering. Teknova specializes in critical reagents for biopharmaceutical products and aims to expedite clinical breakthroughs in life sciences.
Alpha Teknova, Inc. (Nasdaq: TKNO) announced the pricing of its upsized initial public offering (IPO) of 6,000,000 shares at $16.00 each, aiming for gross proceeds of approximately $96.0 million. The underwriters have a 30-day option to purchase an additional 900,000 shares. Trading on Nasdaq is set to begin on June 25, 2021. The offering is expected to close around June 29, 2021, pending customary conditions. Cowen and William Blair are joint book-running managers, with legal counsel provided by Paul Hastings LLP and DLA Piper LLP.